Binance Coin (BNB) is being observed by analysts as 2025 comes to an end. BNB is currently under growing pressure as the token falls below key moving averages. This continues to trail the rest of the cryptocurrency industry. Investors are keeping a close eye on these improvements as potential catalysts for a recovery. At press […]Binance Coin (BNB) is being observed by analysts as 2025 comes to an end. BNB is currently under growing pressure as the token falls below key moving averages. This continues to trail the rest of the cryptocurrency industry. Investors are keeping a close eye on these improvements as potential catalysts for a recovery. At press […]

Binance Coin Eyes a Big Finish: But Can BNB Break the $900 Wall in 2025?

  • BNB is currently under growing pressure as the token falls below key moving averages
  • The coin is on a path to a short-term bullish scenario, indicated by the SMI indicator
  • In November, the potential ROI of the coin this month can be 9.69%

Binance Coin (BNB) is being observed by analysts as 2025 comes to an end. BNB is currently under growing pressure as the token falls below key moving averages. This continues to trail the rest of the cryptocurrency industry. Investors are keeping a close eye on these improvements as potential catalysts for a recovery.

At press time, the coin is trading at $819.66 with a 6.52% decrease rate. The market cap of the coin exceeds $112.92 billion, and the volume of the token is $4.73 billion.

Source: CoinMarketCap

Also Read: Binance Coin (BNB) Faces Pressure Even as Technical Indicators Signal Cooling Trend

2025 Price Forecasts & Technical Outlook of Binance Coin

The data given by TradingView charts shows that the coin is experiencing resistance (yellow) at $840.9. This can go up to $880 if the value of BNB goes above the level of resistance, causing a bullish momentum. The support line (blue) of the coin is at $801. This value can dip to $800 if the coin drops below the level of support.

The relative strength index (RSI) indicates that the coin is being oversold. This suggests that the downward pressure on the token might be overextended. The Stochastic Momentum Index (SMI) suggests that the coin is on a path to a short-term bullish scenario. This is because the SMI line (blue) is above the signal line (orange).

Source: TradingView

The BNB Price Performance data given by CoinGlass dictates that the coin has had an increasing rate of 0.68% in the past 4 hours. But on the other hand, in the 24-hour data, BNB has had a decreasing rate of 6.19%.

Source: CoinGlass

Final Outlook

The current developments in the BNB ecosystem have contributed to a positive sentiment for its trajectory. Recently, many updates, such as the token’s launch pool and Earn programs, have helped bring attention to the coin from traders. Also, the BNB burn mechanism assists in the issue of scarcity, causing value stability.

Source: CoinCodex

According to CoinCodex, the coin might break the $900 wall as the average price of the coin might be $843.79, and the maximum price can be $903.08 in the month of November. The potential ROI of the coin this month can be 9.69%. On the other hand, the average price and maximum price of Binance Coin in December can be $831.87 and $860.06, respectively. The potential ROI of BNB in that month might be 4.46%.

Also Read: Binance Coin (BNB): Bulls Confident to Push It Above $960 This Month

Market Opportunity
Binance Coin Logo
Binance Coin Price(BNB)
$931,42
$931,42$931,42
-0,67%
USD
Binance Coin (BNB) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26